Aucta debuts generic Vimpat
PISCATAWAY, N.J., Feb. 26, 2024 /PRNewswire/ -- Aucta Pharmaceuticals, Inc., a private specialty pharmaceutical company focused on niche generic and branded specialty products, today announced the commercial launch of MOTPOLY XR (lacosamide) extended-release capsules C-V (100, 150 and 200 mg). MOTPOLY XR is approved for the treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg.
Aucta announced FDA approval of a generic version of Trileptal®(oxcarbazepine) oral suspension
Aucta's Generic Oxcarbazepine Receives Approval in the U.S.
Aucta's Generic Formoterol Fumarate Receives Approval in the U.S.
Aucta Pharmaceuticals, Inc. (Aucta) has partnered with Oakrum Pharma, out of St. Louis, Missouri, to announce the U.S. launch of a generic version of JADENU® Sprinkle (Deferasirox Granules) in 90mg, 180mg, and 360mg strengths.
Eton Pharmaceuticals, based in Deer Park, Illinois, has a target action date of March 17, 2020 for its New Drug Application for ET-105, its innovative formulation of lamotrigine. Eton acquired the U.S. marketing rights to the drug in June 2019 from Aucta Pharmaceuticals. The company is seeking approval for the drug as an adjunct therapy for partial seizures, primary generalized tonic-clonic seizures, and generalized seizures of Lennox-Gastaut syndrome in patients two years of age and older.